Patient demographics, disease characteristics, and donor sources
| Characteristics . | Standard-dose busulfan group (n = 25) . | Lower-dose busulfan group (n = 20) . | P . |
|---|---|---|---|
| Median age (y) | 8.2 (4.3-31.4) | 9.8 (4.3-44) | .86 |
| <10 | 15 | 11 | .77 |
| ≥10 | 10 | 9 | |
| Gender | |||
| Males | 12 | 8 | .76 |
| Females | 13 | 12 | |
| Indication for HCT | .82 | ||
| Severe single-lineage cytopenia | 3 | 2 | |
| Severe aplastic anemia | 17 | 12 | |
| Myelodysplastic syndrome | 5 | 6 | |
| Low-grade | 3 | 4 | |
| High-grade | 2 | 2 | |
| Unrelated donors | 19 | 20 | .027 |
| 8/8 allele-matched | 16/19 | 10/20 | .041 |
| 7/8 allele-matched | 3/19 | 10/20 | |
| Mismatched related donors (7/8, 6/8, 5/8, and 4/8 allele-matched) | 6 | 0 | |
| CD34+ cells/kg (median) | 10.5 × 106 (1.1-42.7) | 14.6 × 106 (3-63.3) | .044 |
| CD3 cells/kg (median) | 0.4 (0-5) | 0.95 (0.1-5) | .68 |
| Median follow-up (mo) | 54.9 (39.9-76.8) | 26.6 (17.36-39.62) | < .0001 |
| Characteristics . | Standard-dose busulfan group (n = 25) . | Lower-dose busulfan group (n = 20) . | P . |
|---|---|---|---|
| Median age (y) | 8.2 (4.3-31.4) | 9.8 (4.3-44) | .86 |
| <10 | 15 | 11 | .77 |
| ≥10 | 10 | 9 | |
| Gender | |||
| Males | 12 | 8 | .76 |
| Females | 13 | 12 | |
| Indication for HCT | .82 | ||
| Severe single-lineage cytopenia | 3 | 2 | |
| Severe aplastic anemia | 17 | 12 | |
| Myelodysplastic syndrome | 5 | 6 | |
| Low-grade | 3 | 4 | |
| High-grade | 2 | 2 | |
| Unrelated donors | 19 | 20 | .027 |
| 8/8 allele-matched | 16/19 | 10/20 | .041 |
| 7/8 allele-matched | 3/19 | 10/20 | |
| Mismatched related donors (7/8, 6/8, 5/8, and 4/8 allele-matched) | 6 | 0 | |
| CD34+ cells/kg (median) | 10.5 × 106 (1.1-42.7) | 14.6 × 106 (3-63.3) | .044 |
| CD3 cells/kg (median) | 0.4 (0-5) | 0.95 (0.1-5) | .68 |
| Median follow-up (mo) | 54.9 (39.9-76.8) | 26.6 (17.36-39.62) | < .0001 |